Insider · CIK 0001855927
Glenn Sobotka
Files at ASTH (Apollo Medical Holdings, Inc.). First filing -, latest -.
In brief
Glenn Sobotka files SEC Form 4 as officer at ASTH (Apollo Medical Holdings, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Glenn Sobotka has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 7, 2026 | ASTH Apollo Medical Holdings, Inc. | DDisposition to issuer Common Stock | -11,793 | $0.00 | $0 | 2,246 | Aug 11, 2026 |
| Mar 26, 2026 | ASTH Apollo Medical Holdings, Inc. | FTax withholding Common Stock | -662 | $24.27 | $16k | 14,039 | Mar 30, 2026 |
| Mar 26, 2025 | ASTH Apollo Medical Holdings, Inc. | AGrant or award Common Stock | +6,432 | $0.00 | $0 | 6,432 | Mar 28, 2025 |
| Mar 26, 2025 | ASTH Apollo Medical Holdings, Inc. | AGrant or award Common Stock | +8,269 | $0.00 | $0 | 14,701 | Mar 28, 2025 |
Questions about Glenn Sobotka
Answered from the filings on this page, as of the latest one.
Is Glenn Sobotka buying or selling?
Glenn Sobotka has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Glenn Sobotka's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Glenn Sobotka has 0.
Where does Glenn Sobotka file Form 4?
Glenn Sobotka has filed Form 4 at ASTH (Apollo Medical Holdings, Inc.) as Chief Accounting Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.